| Date | Title | Description |
| 27.07.2024 | Navigating the Waters of Shareholder Rights: A Look at Recent Investigations | In the turbulent sea of corporate mergers and acquisitions, shareholders often find themselves adrift. Recent investigations by Halper Sadeh LLC shine a spotlight on potential breaches of fiduciary duty and securities law violations. These ... |
| 25.07.2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders | NEW YORK, July 25, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders rela... |
| 24.03.2023 | Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023 | BOSTON, MA / ACCESSWIRE / March 24, 2023 / Pieris Pharmaceuticals, Inc. PIRS,a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and ... |
| 28.07.2022 | Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022 | BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, ca... |
| 02.06.2022 | Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference | BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, can... |
| 18.02.2022 | Research on therapeutics against COVID-19: Ilse Aigner visits Pieris | State Parliament President Ilse Aigner and other political representatives visited the biotech company Pieris Pharmaceuticals in Hallbergmoos to see how research is progressing. Among other things, Pieris is developing a therapeutic against... |
| 14.01.2022 | Pieris Pharmaceuticals : Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa | January 14, 2022
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4-1BB/HER2 Bispecific Cinrebafusp Alfa
BOSTON, MA / ACCESSWIRE / January 14,2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a cl... |
| 03.01.2022 | Pieris Pharmaceuticals : Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402 | January 3, 2022
Pieris Pharmaceuticals Announces
Successful Completion of Safety Milestone
and Initiation of Efficacy Portion of Phase
2a Trial of PRS-060/AZD1402
BOSTON, MA / ACCESSWIRE / January 3, 2022 /Pieris Pharmaceuticals, Inc. (NASD... |
| 11.11.2021 | Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences | November 11, 2021
Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE /November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biother... |
| 08.11.2021 | Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012 | November 8, 2021
Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS- 344/S095012
BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 /Pieris Pharmaceuticals, Inc. (N... |
| 02.11.2021 | Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update | November 2, 2021
Pieris Pharmaceuticals Reports Third
Quarter 2021 Financial Results and
Provides Corporate Update
Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00
AM EDT
Dosing completed in part 1a of phase ... |
| 26.10.2021 | Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021 | October 26, 2021
Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
BOSTON, MA / ACCESSWIRE / October 26, 2021 /Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biot... |
| 06.10.2021 | Pieris Pharmaceuticals : Announces Appointments of Chief Financial Officer and Chief Business Officer | October 6, 2021
Pieris Pharmaceuticals Announces
Appointments of Chief Financial Officer
and Chief Business Officer
BOSTON, MA / ACCESSWIRE / October 6,2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology compan... |
| 15.09.2021 | Munich proves its strength against COVID-19 at
22. Pharma Trend - Image and Innovation Award | On September 14, the winners of the "Most Innovative Product" award in the category of leap innovations were announced at the "Pharma Trend - Image & Innovation Award". Formycon convinced ahead of Ethris, with third ... |
| 09.09.2021 | Pieris Pharmaceuticals : to Participate in Upcoming Investor Conferences | September 9, 2021
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / September 9,2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biother... |
| 24.08.2021 | Pieris Pharmaceuticals : Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor | August 24, 2021
Pieris Pharmaceuticals Announces PRS- 220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
BOSTON, MA / ACCESSWIRE / August 24,2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechno... |
| 04.08.2021 | Pieris Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Corporate Update | August 4, 2021
Pieris Pharmaceuticals Reports Second
Quarter 2021 Financial Results and
Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT
Announced inhaled program PRS-220 for ... |
| 03.08.2021 | Pieris Pharmaceuticals : Strengthens Executive R&D Leadership Team | August 3, 2021
Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team
Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical Officer
Shane Olwill, Ph.D., promoted to Chief Development Officer
BOSTON, MA / ACCESSWIRE / August 3... |
| 25.06.2021 | Pieris Pharmaceuticals : Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVI... | June 25, 2021
Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post- COVID-19 Pulmonary Fibrosis
PRS... |
| 24.06.2021 | Pieris Pharmaceuticals : Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer | June 24, 2021
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
BOSTON, MA / ACCESSWIRE / June 24,2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnolo... |
| 26.05.2021 | Billion-dollar deal for Pieris | Munich-based Pieris enters into a research collaboration with Roche subsidiary Genentech on therapies for respiratory diseases and ophthalmology. Pieris will receive USD 20 million as an upfront payment and is eligible for more than USD 1.4... |
| 25.05.2021 | PIERIS PHARMACEUTICALS, INC.
Pieris Pharmaceuticals : Announces Respiratory and Ophthalmology Collaboration with Genentech | May 25, 2021
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milesto... |
| 20.05.2021 | PIERIS PHARMACEUTICALS, INC.
Pieris Pharmaceuticals : to Present at the Jefferies 2021 Virtual Healthcare Conference | Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
Download PDF
BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel b... |
| 12.04.2021 | PIERIS PHARMACEUTICALS, INC.
Pieris Pharmaceuticals : Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095... | BOSTON, MA - Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, t... |
| 30.03.2021 | PIERIS PHARMACEUTICALS, INC.
Pieris Pharmaceuticals : Reports Full-Year 2020 Financial Results and Provides Corporate Update | Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update
Download PDF
Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT
Pieris achieves $13 million milestone from Astr... |
| 25.03.2021 | PIERIS PHARMACEUTICALS, INC.
Pieris Pharmaceuticals : Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinreba... | Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA(R) (tucatinib) in Gastric Cancer, and Str... |
| 04.11.2020 | PIERIS PHARMACEUTICALS, INC.
Pieris Pharmaceuticals : Reports Third Quarter 2020 Financial Results and Provides Corporate Update | Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Download PDF
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 4, 2020 AT 8:00 AM EST
PRS-060/AZD1402 first regulatory submis... |
| 04.11.2020 | Pieris Pharmaceuticals : Reports Third Quarter 2020 Financial Results and Provides Corporate Update | Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Download PDF
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 4, 2020 AT 8:00 AM EST
PRS-060/AZD1402 first regulatory submis... |
| 21.07.2020 | Pieris slammed with FDA hold; Biogen adds PhIV for Spinraza | → Boston-based Pieris $PIRS has been forced to hit the brakes on a slate of Phase I studies for its 4-1BB/HER2 fusion protein drug PRS-343 after the FDA hit the company with a partial hold. The biotech can continue to dose patient... |
| 04.11.2019 | Tmunity teams up with Oncora Medical; T3D receives additional funding for Alzheimer's study | → Usman “Oz” Azam–led Tmunity Therapeutics — which recently bagged $75 million, bringing their total to-date funding to $231 million — has entered into a collaboration with Oncora Medical to access Oncora’s real-wo... |
| 06.09.2019 | Randy Schatzman jumps to the helm of another start-up; Novo Nordisk vet lands top post at Macrophage Pharma | → In biotech, long-term survival in the executive ranks can depend a lot on the quality of your connections in the venture/investing side of the business.
Randy Schatzman Bolt Biotherapeutics
So when Randy Schatzman exit... |
| 11.08.2017 | Novartis veteran David Epstein takes leadership role at Rubius | ⇨ Novartis vet David Epstein is expanding his role at Rubius, taking the executive chairman’s post at the cell therapy company. In taking the post, the Flagship exec noted: “I believe Rubius’ pioneering of the next g... |
| 04.05.2017 | AstraZeneca and Pieris Pharmaceuticals collaborate on treatments for respiratory diseases | AstraZeneca and Pieris Pharmaceuticals collaborate on treatments for respiratory diseases
04-05-2017
AstraZeneca has announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals, Inc. to develop novel inhaled drug... |
| 03.05.2017 | AstraZeneca commits $57.5M to seed Anticalin R&D pact with Pieris, a biotech on a roll | Stephen Yoder
Boston-based Pieris Pharmaceuticals has rolled out its second big-money collaboration in the last four months, this time reeling in Big Pharma player AstraZeneca, which wants to see just how effective the biot... |
| 27.02.2017 | Pieris inks a licensing deal for Japan; Kindler joins Pharma Two B board with $30M raise; Ampio plots new pain study | Stephen Yoder, Pieris CEO
→ Boston-based Pieris $PIRS has optioned a licensing pact giving ASKA Pharmaceutical development and commercialization rights for the anemia drug PRS-080 in Japan and certain other Asian market... |
| 18.12.2014 | Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million | Completion of alternative public offering in which Pieris AG becomes a wholly-owned subsidiary of Pieris Pharmaceuticals, Inc.
Freising, Germany – Pieris Pharmaceuticals, Inc. (OTC:PIRS) (formerly Marika, Inc.), a Nevada corporation, annou... |
| 19.10.2011 | Pieris Receives EUR 6 million Grant to Novel Anticalin Therapeutic to Treat Anemia | Freising, Germany - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris’ proprietary hepcidin antagonist program, the company announced today the posit... |
| 27.03.2008 | Pieris Raises EUR 25 million in Series B Financing Round | FREISING-WEIHENSTEPHAN, Germany - Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced today the closing of a Series B financing round.
Led by new investor OrbiMe... |
